5:15 PM
 | 
Jan 20, 2012
 |  BC Extra  |  Company News

Alnylam restructuring

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it will restructure and reduce headcount by 61 (35%) to 115 following a decision this month to partner three of the five RNAi therapeutic programs it is hoping to move into advanced clinical development by 2015 as part of its "Alnylam 5x15 strategy." Alnylam will focus internal development on...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >